| Prev Close | 2.27 |
| Open | 2.26 |
| Day Low/High | 2.13 / 2.27 |
| 52 Wk Low/High | 0.93 / 2.88 |
| Volume | 300.85K |
| Avg Volume | 358.80K |
| Exchange | NASDAQ |
| Shares Outstanding | 45.16M |
| Market Cap | 51.94M |
| EPS | -0.50 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th
Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases
Sustained Release Technology Well Tolerated and Provides Pain Reduction
Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th
Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds
Investors in pSivida Corp saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
